Trastuzumab (Herceptin) is the first clinically approved monoclonal antibody against HER2 mutant cancer [38], and its antiproliferative effects have also been shown to be mediated through FOXO3 and its downstream target Survivin (BRC5) via the PI3K-Akt pathway [39]. Here, FOXO3 is linked to cancer.